Track topics on Twitter Track topics that are important to you
BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.
Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html
Interested? Contact firstname.lastname@example.org
Veryan has developed three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The initial objective was to investigate the presence of, and effects arising from, secondary flows in a 3D...
Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anatomies with neck angulations of up to 90°. The Aor...
Boston Scientific is a global medical device company, the 8th largest (based on annual sales, which were over $8 billion in 2010). It is the world's second largest maker of heart devices; products of note include Taxus Express stent and Cognis card...
Variant Angina (or Prinzmetal Angina) is pain in chest region caused by coronary artery spasm. Prinzmetal's Angina, or coronary artery spasm, is an uncommon condition seen in both men and women. Because the spasm almost always terminates spontaneousl...
Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets,...
BioPortfolio has created approx 200 Twitter accounts with currently (June 2015 - 46,000 Twitter Followers) to support our users interest in keeping upto date on the latest news, research papers, reports and clinical trials on a selected range of importan...
Thrombosis is the formation of a blood clot inside a blood vessel, blocking a vein (venous thrombosis) or artery (arterial thrombosis). Venous Arterial Thromboembolism (VAT) is caused when some or all of a clot detaches and is moved within the blood stre...
Naturally occurring vitamin E exists in eight chemical forms (alpha-, beta-, gamma-, and delta-tocopherol and alpha-, beta-, gamma-, and delta-tocotrienol) that have varying levels of biological activity. Alpha- (or α-) tocopherol is the only form ...
Syndrome X may refer to: Cardiac syndrome X Cardiac syndrome X is angina (chest pain) with signs associated with decreased blood flow to heart tissue but with normal coronary arteries. Some studies have found increased risk of other vasospastic disor...